News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioCon Limited (BIOCON.NS) Collaborates With Advaxis, Inc. For "ADXS-HPV" A Novel Cancer Immunotherapy


1/22/2014 8:37:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BANGALORE, India & PRINCETON, N.J.--(BUSINESS WIRE)--Biocon Ltd., (BIOCON.BO), Asia’s premier biotechnology company, and Advaxis, Inc., (NASDAQ: ADXS), a leader in developing the next generation of cancer immunotherapies, announced today that they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES